๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Gemcitabine-based therapy in pancreas cancer : Gemcitabine-docetaxel and other novel combinations

โœ Scribed by Andrew D. Jacobs

Book ID
102103803
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
69 KB
Volume
95
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Since its approval in 1998 by the Food and Drug Administration, gemcitabine has rapidly become accepted as a standard part of palliative therapy for patients with advanced pancreatic cancer. It has modest activity when used as a single agent, and this has led to numerous studies combining it with other active agents, including cytotoxic as well as biologic and targeted therapies. Numerous Phase II studies suggest that the combinations may have greater activity than single agent therapy. However, randomized trials concerning this are still in progress. In the current article, a variety of gemcitabine-based novel combinations showing promising activity are reviewed.

๐Ÿ“œ SIMILAR VOLUMES

Verteporfin-based photodynamic therapy o
Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines
โœ Jonathan P. Celli; Nicolas Solban; Alvin Liang; Stephen P. Pereira; Tayyaba Hasa ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 507 KB

Background and Objective: Pancreatic cancer is notoriously difficult to treat and resistant to virtually all therapeutics including gemcitabine, the standard front line agent for palliative chemotherapy. Early clinical studies point to a potential role for photodynamic therapy (PDT) in the managemen